Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Any apneic episodes · preterm infants at risk for apnea

Methylxanthine may leads to lower any apneic episodes compared with placebo or control (low certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.19 [0.09, 0.41]
2 studies · 104 participants
Low

Any apneic episodes · preterm infants with apnea

It is very uncertain whether methylxanthine changes any apneic episodes compared with placebo or control (very low certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.7 [0.3, 1.62]
1 study · 43 participants
Very low

Any apneic episodes · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine probably leads to lower any apneic episodes compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.31 [0.18, 0.52]
4 studies · 167 participants
Moderate